Iron and fatigue with low ferritin
Fatigue study in menstruating women without anemia and its applicability.
Key points
- In menstruating women with fatigue, ferritin below 50 µg/L and no anemia, fatigue score decreased more with iron than placebo over 12 weeks. With similar fatigue, discuss iron measures with a doctor before choosing a supplement. [1] See the evidence 1
- Ferritin below 50 µg/L was a study eligibility condition, not a universal deficiency threshold. Menstruation alone also does not establish iron deficiency. [2] [1] See the evidence 1
Practical guide
Check the conclusions and whether they apply to your situation.
Fatigue and iron measures are assessed in the individual context.
Key points
Why these conclusions
Fatigue study
Menstruating women aged 18–53 with fatigue, ferritin below 50 µg/L and no anemia received 80 mg elemental iron daily as prolonged-release sulfate or placebo for 12 weeks. Fatigue score decreased more with iron; certainty is low. [1]
Menstruation, pregnancy, diet and age change the likelihood of low iron stores, but do not by themselves establish deficiency. The fatigue study result in women with ferritin <50 µg/L cannot be applied to people with normal iron stores. Ferritin below 50 µg/L was a study eligibility condition, not a universal deficiency threshold; ferritin may rise during inflammation. [2] [1]
In hereditary hemochromatosis iron can accumulate in the body. Iron supplements should be avoided with this condition; general intake limits are not permission to take them. EFSA established a safe level of total intake of 40 mg/day from all sources for adults, including pregnant and breastfeeding women, not a formal UL; the US UL for healthy adults is 45 mg/day from food and supplements. A doctor may prescribe a higher dose when indicated. [3] [2]
Ferrous sulfate can cause constipation, nausea and abdominal discomfort. In a review of 20 placebo-controlled trials (3,168 adults), ferrous sulfate caused gastrointestinal adverse events more often than placebo: OR 2.32 (95% CI 1.74–3.08). [4]
Fatigue score decreased by 47.7% with iron and 28.8% with placebo over 12 weeks; difference in changes −18.9 percentage points (95% CI −34.5 to −3.2), p=0.02.
| Parameter | Data |
|---|---|
| Result | Fatigue score reduction: 47.7% with iron versus 28.8% with placebo; difference in changes −18.9 percentage points (95% CI −34.5 to −3.2); p=0.02. |
| Participants | 198 menstruating women aged 18–53 with fatigue, ferritin below 50 µg/L and hemoglobin above 12 g/dL |
| Form | Oral prolonged-release ferrous sulfate (Tardyferon) |
| Dose | 80 mg elemental iron daily |
| Dose basis | 80 mg elemental iron daily |
| Comparator | Placebo |
| Duration | 12 weeks |
| Confidence | 2/4: Precision: Small sample or substantial uncertainty of the confidence interval; Consistency: One comparison or heterogeneity cannot be assessed.; Applicability: The result was measured directly in the specified group.; Possible publication bias: No specific data; it cannot be excluded.; Study methods: Small or selected study, participant dropout, reporting or incomplete description of methods |
| Evidence base | 1 trial |
| Sources | [1] |
Menstruation, pregnancy, diet and age change the likelihood of low iron stores, but do not by themselves establish deficiency. The fatigue study result in women with ferritin <50 µg/L cannot be applied to people with normal iron stores. Ferritin below 50 µg/L was a study eligibility condition, not a universal deficiency threshold; ferritin may rise during inflammation.
Menstruation, pregnancy, diet and age change the likelihood of low iron stores, but do not by themselves establish deficiency. The fatigue study result in women with ferritin <50 µg/L cannot be applied to people with normal iron stores. Ferritin below 50 µg/L was a study eligibility condition, not a universal deficiency threshold; ferritin may rise during inflammation. [2] [1]
In hereditary hemochromatosis iron can accumulate in the body. Iron supplements should be avoided with this condition; general intake limits are not permission to take them. EFSA established a safe level of total intake of 40 mg/day from all sources for adults, including pregnant and breastfeeding women, not a formal UL; the US UL for healthy adults is 45 mg/day from food and supplements. A doctor may prescribe a higher dose when indicated.
In hereditary hemochromatosis iron can accumulate in the body. Iron supplements should be avoided with this condition; general intake limits are not permission to take them. EFSA established a safe level of total intake of 40 mg/day from all sources for adults, including pregnant and breastfeeding women, not a formal UL; the US UL for healthy adults is 45 mg/day from food and supplements. A doctor may prescribe a higher dose when indicated. [3] [2]
Ferrous sulfate can cause constipation, nausea and abdominal discomfort. In a review of 20 placebo-controlled trials (3,168 adults), ferrous sulfate caused gastrointestinal adverse events more often than placebo: OR 2.32 (95% CI 1.74–3.08).
Ferrous sulfate can cause constipation, nausea and abdominal discomfort. In a review of 20 placebo-controlled trials (3,168 adults), ferrous sulfate caused gastrointestinal adverse events more often than placebo: OR 2.32 (95% CI 1.74–3.08). [4]
Sources
- Effect of iron supplementation on fatigue in nonanemic menstruating women with low ferritin: a randomized controlled trial. https://pmc.ncbi.nlm.nih.gov/articles/PMC3414597/
- Iron - Health Professional Fact Sheet. https://ods.od.nih.gov/factsheets/Iron-HealthProfessional/
- Scientific opinion on the tolerable upper intake level for iron. https://www.efsa.europa.eu/en/plain-language-summary/scientific-opinion-tolerable-upper-intake-level-iron
- Ferrous Sulfate Supplementation Causes Significant Gastrointestinal Side-Effects in Adults: A Systematic Review and Meta-Analysis. https://pmc.ncbi.nlm.nih.gov/articles/PMC4336293/
Methodology: Subpages evidence-led supplement pipeline v1